Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04561115
Other study ID # GC1902
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2, 2020
Est. completion date March 28, 2022

Study information

Verified date June 2023
Source Grifols Therapeutics LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate bioequivalence of IVIG-PEG with Gamunex-C (IVIG-C) at steady-state as determined by comparing total Immunoglobulin G (IgG) area under the concentration-time curve during the defined dosing interval ([AUC0-τ] either every 3 weeks [AUC0-21 days] or every 4 weeks [AUC0-28 days]) and maximum concentration in a dosing interval (Cmax) in participants diagnosed with primary humoral immunodeficiency (PI) currently receiving chronic IVIG replacement treatment.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date March 28, 2022
Est. primary completion date March 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male or female between 18 and 75 years of age (inclusive) at Screening - Documented and confirmed pre-existing diagnosis of PI with features of hypogammaglobulinemia requiring IV IgG replacement therapy including but not limited to the following humoral-based immunodeficiency syndromes (example, X-linked agammaglobulinemia, common variable immunodeficiency), and combined immunodeficiency syndromes without lymphocytopenia (example, hyper immunoglobulin M [IgM] immunodeficiency syndrome). - IgG trough level =500 milligrams per deciliter (mg/dL) at screening visit. Note: Patients entering Group 1 must additionally have trough levels =500 mg/dL documented within the previous year. For patients entering Group 2, if Screening trough levels are not =500 mg/dL, the subject will be a Screen Failure, but may be rescreened following dose adjustment of their original IV IgG replacement therapy regimen and recording an IgG trough level =500 mg/dL - Has not had an SBI within the last 6 months prior to screening or during the screening. - Medical records are available to document diagnosis, previous infections, and treatment. - Willing to comply with all aspects of the study protocol, including blood sampling, for the duration of the study. - Signed and dated a written informed consent form (ICF) confirming his or her willingness to participate in study GC1902. Exclusion Criteria: - Has an acquired medical condition that is known to cause secondary immune deficiency such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000per microliters (1000/µL) [1.0 x 10^9/L]), or human immunodeficiency virus (HIV) infection/acquired immune deficiency syndrome (AIDS). - Has known selective Immunoglobulin A (IgA) deficiency (with or without antibodies to IgA). (Note: exclusion is for the specific diagnostic entity. It does not exclude other forms of primary humoral immunodeficiency which have decreased IgA in addition to decreased IgG requiring IgG replacement). - Has isolated IgG subclass deficiency or an isolated specific antibody deficiency disorder, or transient hypogammaglobulinemia of infancy - The subject has had a known serious adverse reaction to immunoglobulin or any severe anaphylactic reaction to blood or any blood-derived product. - Has a history of thrombotic complications following IVIG therapy. - Has a history of or current diagnosis of deep venous thrombosis (DVT) or thromboembolism (e.g., myocardial infarction, cerebrovascular accident or transient ischemic attack); history refers to an incident in the year prior to the Screening Visit or 2 episodes over lifetime or has thrombosis risk factors (e.g., prolonged immobilization, use of estrogens, indwelling central vascular catheters). - Has a known hyperviscosity syndrome or hypercoagulable states. - Has liver enzyme levels (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gammaglutamyl transferase [GGT], or lactate dehydrogenase [LDH]) greater than 2.5 times the upper limit of normal (ULN) at the screening visit as defined by the testing laboratory. - Has pre-existing renal impairment (defined by serum creatinine greater than 1.5 times the ULN or blood urea nitrogen [BUN] greater than 2.5 times the ULN, or any subject who is on dialysis) at the screening visit or any history of acute renal injury. - Has clinically significant history of drug or alcohol abuse or dependence in the opinion of the Investigator (must be within the past 12 months and noted in the subject's medical records or documented at screening). - Clinical evidence of any significant acute or chronic medical condition (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing state) that, in the opinion of the Investigator, may interfere with the conduct of the study or may place the subject at undue medical risk. - Females of childbearing potential who are pregnant, have a positive pregnancy test at Screening (human chorionic gonadotropin [HCG]-based assay), are breastfeeding, or unwilling to practice a highly effective method of contraception (eg, oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device [IUD] or intrauterine system [IUS], condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study. Note: True abstinence: When this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods], declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception). - Receiving any of the following medications: (a) immunosuppressants including chemotherapeutic agents, (b) immunomodulators, (c) long-term systemic corticosteroids defined as daily dose >1 mg of prednisone equivalent/kg/day for >30 days. Note: Intermittent courses not exceeding >1mg of prednisone equivalent/kg/day for >30 days would not exclude the subject. Inhaled or topical corticosteroids are allowed. - Has uncontrolled arterial hypertension (systolic blood pressure [SBP] >160 mm Hg and/or diastolic blood pressure [DBP] >100 mm Hg) - Has hemoglobin <11 g/dL at the Screening Visit - Unable or unwilling to provide a storage serum sample at the Screening Visit. Note: A pre-treatment serum sample to be stored at -94°F (-70ºC) for possible future testing is required. - Received any live virus vaccine within 5 months prior to the Screening Visit and not willing to postpone receiving any live virus vaccines until 6 months after completing study treatment - Has a known previous infection with or clinical signs and symptoms consistent with current hepatitis B virus (HBV) or hepatitis C virus (HCV) infection - Has participated in another clinical trial within 30 days prior to Screening or has received any investigational product, with the exception of other IgG products, within the previous 3 months prior to the Screening Visit

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Gamunex-C
Intravenous infusion.
IVIG-PEG
Intravenous infusion.

Locations

Country Name City State
United States Alabama Allergy & Asthma Center Birmingham Alabama
United States Institute for Asthma and Allergy Chevy Chase Maryland
United States Optimed Research, LLC Columbus Ohio
United States AARA Research Center Dallas Texas
United States Allergy Partners of North Texas Research Dallas Texas
United States Allergy, Asthma & Immunology Clinic, P.A. Irving Texas
United States Allergy Associates of the Palm Beaches PA North Palm Beach Florida
United States Washington University Saint Louis Missouri
United States The South Bend Clinic Center for Research South Bend Indiana
United States Allergy, Asthma and Immunology Center, P.C. Tulsa Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Grifols Therapeutics LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC (0-7): Area Under the Concentration Time Curve Over a Dosing Interval of Either Every 3 Weeks [AUC0-21 Days] or Every 4 Weeks [AUC0-28 Days] for Total Immunoglobulin G (IgG) AUC (0-7 days) is calculated as AUC (0-21 days)/3 for subjects with a dosing frequency of every 3 weeks and as AUC(0-28 days)/4 for subjects with a dosing frequency of every 4 weeks. Pre-dose, within 10 minutes of last infusion completion, at 1, 3, 6, 24, 48 hours and 4, 7, 14 and 21 days (up to 3 weeks), and 28 days (up to 4 weeks - only for subjects on a 4-week dosing schedule) post-infusion
Primary Cmax: Maximum Concentration in a Dosing Interval for Total IgG Pre-dose, within 10 minutes of last infusion completion, at 1, 3, 6, 24, 48 hours, and 4, 7, 14, 21 and 28 days post-infusion (up to 4 weeks)
Secondary Rate of Serious Bacterial Infections (SBIs) The rate of SBI events per participant per year during treatment was calculated as the total number of SBI events divided by the total duration of exposure in years across all participants. The 2-sided 98% confidence interval (CI) was determined from a generalized linear model for Poisson regression for the log-transformed number of events with log-transformed duration of exposure in years as an offset variable. Baseline up to 6 months for each period, i.e., overall GC treatment phase and overall IVIG-PEG treatment phase with an aggregate duration of up to 12 months
Secondary Rate of Events Per Participant Per Year in Participants With Any Kind of Infection Rate of events per participant per year is calculated as the total number of events divided by the total duration of exposure in years across all participants. Any kind of infections included serious/nonserious including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, pneumonia, acute bronchitis, infectious diarrhea etc.) as determined by the Investigator. Baseline up to 6 months for each period, i.e., overall GC treatment phase and overall IVIG-PEG treatment phase with an aggregate duration of up to 12 months
Secondary Rate of Days Per Person Per Year That Participants Were on Antibiotics Rate of days per person per year is calculated as the total number of days divided by the total duration of exposure in years across all participants. Antibiotics included prophylactic and therapeutic. Baseline up to 6 months for each period, i.e., overall GC treatment phase and overall IVIG-PEG treatment phase with an aggregate duration of up to 12 months
Secondary Number of Participants Hospitalized Due to Infection Hospitalization was considered only in cases of hospital admission (including emergency room stay) for equal or more than 24 hours. Baseline up to 6 months for each period, i.e., overall GC treatment phase and overall IVIG-PEG treatment phase with an aggregate duration of up to 12 months
Secondary Rate of Days of Work/School/Daily Activities Missed Per Participant Due to Infections and Their Treatment Rate of days per person per year is calculated as the total number of days divided by the total duration of exposure in years across all participants. Baseline up to 6 months for each period, i.e., overall GC treatment phase and overall IVIG-PEG treatment phase with an aggregate duration of up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT04566692 - A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency Phase 4
Completed NCT01465958 - Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency Phase 4
Completed NCT01581593 - Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Phase 3
Completed NCT02881437 - IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia Phase 4
Recruiting NCT06092528 - Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency N/A
Active, not recruiting NCT03576742 - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Completed NCT03907241 - CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL Phase 3
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Completed NCT02806986 - Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3
Completed NCT03339778 - The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations N/A
Enrolling by invitation NCT00895271 - Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Recruiting NCT03206099 - NIAID Centralized Sequencing Protocol
Completed NCT02503293 - A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Phase 4
Recruiting NCT03610802 - Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
Completed NCT03815357 - What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
Completed NCT02269163 - Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% Phase 3
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Not yet recruiting NCT02123615 - ASIS for GAMMAGARD in Primary Immunodeficiency Phase 1/Phase 2
Completed NCT02604810 - Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3
Completed NCT00278954 - Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Phase 3